Kenya has made a historic leap in healthcare with the introduction of advanced nuclear therapy, a revolutionary cancer treatment now available at the Aga Khan University Hospital, Nairobi (AKUHN).
The hospital is the first in the country — and among a few in Africa — to offer Lutetium-177 PSMA therapy, a next-generation treatment for advanced prostate cancer that has stopped responding to conventional therapies.
Breakthrough in precision cancer treatment
The Lutetium-177 PSMA therapy uses a radioactive compound that selectively binds to Prostate-Specific Membrane Antigen (PSMA) proteins found on prostate cancer cells. Once attached, it delivers a targeted dose of radiation that kills the cancer cells while sparing healthy tissues.
Dr. Samuel Nguku, Head of Nuclear Medicine at AKUHN, said the therapy marks a major shift toward precision oncology in Kenya.
“This is a targeted treatment that focuses radiation precisely where it’s needed. It offers hope to patients whose cancer has resisted other forms of therapy,” Dr. Nguku explained.
Unlike traditional chemotherapy, the therapy significantly reduces side effects and improves patients’ quality of life.
Prostate cancer remains a major health challenge
Prostate cancer is the most common cancer among men in Kenya and one of the leading causes of cancer deaths nationwide. Data from the National Cancer Institute of Kenya (NCI-K) shows thousands of new cases are diagnosed each year, many at late stages.
Until now, patients requiring advanced treatment often traveled abroad, particularly to India or South Africa, at great financial cost. The introduction of Lutetium-177 PSMA therapy in Kenya will help close that gap and improve access to life-saving care.
Prof. Mansoor Saleh, Chair of Haemato-Oncology at AKUHN, noted that the therapy aligns with Kenya’s push to strengthen local capacity for specialized healthcare.
“This development means Kenyan patients can now access world-class cancer care locally. It’s a significant step toward medical independence,” said Prof. Saleh.
Toward a Regional Centre for Advanced Cancer Care
The introduction of nuclear therapy in Kenya places the country on track to become a regional hub for advanced oncology services. Experts say that as local expertise grows, similar therapies may soon be extended to other cancers, including neuroendocrine and thyroid tumors.
Prof. Saleh added that continued investment and collaboration will be key to ensuring equitable access and affordability for all Kenyans.
A symbol of hope for cancer patients
For thousands of men battling prostate cancer, the launch of Lutetium-177 PSMA therapy is a beacon of hope. It represents Kenya’s commitment to adopting world-class technology and delivering compassionate, patient-centered care.
As Kenya continues to advance in nuclear medicine, the country is taking a decisive step toward a future where cutting-edge cancer treatment is no longer a privilege for a few, but a right for all.
